| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider activity in SNSE over the last quarter tilts toward selling: insiders offloaded a net 34,359 shares worth roughly $600K.
Classified under Biotechnology (Health Care sector), SNSE's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| COO | 1.24M | - | - | |
| Pres | 220.0K | - | - | |
| 10% | 130.6K | $2.61M | - | |
| 10% | 130.6K | $2.61M | - | |
| Other | 80.0K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2021 | Peyer James | Director, 10% Owner | Buy | 817 | $15.25 | $12,459.25 | - | -18.1% | -81.9% | |
| Mar 8, 2021 | Peyer James | Director, 10% Owner | Buy | 1,000 | $15.25 | $15,249.00 | - | - | - | |
| Mar 8, 2021 | Cambrian Biopharma Inc | 10% Owner | Buy | 1,000 | $15.25 | $15,249.00 | - | - | - | |
| Mar 5, 2021 | Peyer James | Director, 10% Owner | Buy | 8,000 | $13.75 | $110,000.00 | +0.2% | - | - | |
| Mar 5, 2021 | Cambrian Biopharma Inc | 10% Owner | Buy | 8,000 | $13.75 | $110,000.00 | +0.2% | - | - | |
| Mar 4, 2021 | Cambrian Biopharma Inc | 10% Owner | Buy | 5,000 | $15.16 | $75,800.00 | - | - | - | |
| Mar 4, 2021 | Peyer James | Director, 10% Owner | Buy | 5,000 | $15.16 | $75,800.00 | - | - | - | |
| Mar 2, 2021 | Cambrian Biopharma Inc | 10% Owner | Buy | 3,000 | $16.25 | $48,750.00 | - | - | - | |
| Mar 2, 2021 | Peyer James | Director, 10% Owner | Buy | 3,000 | $16.25 | $48,750.00 | - | - | - | |
| Feb 26, 2021 | Peyer James | Director, 10% Owner | Buy | 5,000 | $16.25 | $81,250.00 | +0.1% | - | - |